ARS Pharmaceuticals (SPRY) Net Income Growth (1y) (2021 - 2026)
ARS Pharmaceuticals (SPRY) Net Income Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,200.25 Bn | 66,199.96 Bn | - | -0.46% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 63.48% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 1,228.66% |
| 10 | ARS Pharmaceuticals | 567.98 Mn | 367.01 Mn | - | -156.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -156.94% |
| Dec 31, 2025 | -192.39% |
| Sep 30, 2025 | 27.30% |
| Jun 30, 2025 | -229.75% |
| Mar 31, 2025 | 58.93% |
| Dec 31, 2024 | 571.87% |
| Sep 30, 2024 | 98.99% |
| Jun 30, 2024 | 99.82% |
| Mar 31, 2024 | 99.77% |
| Dec 31, 2023 | 33.83% |
| Sep 30, 2023 | -101,915.07% |
| Jun 30, 2023 | -282,138.23% |
| Mar 31, 2023 | -339,646.93% |
| Dec 31, 2022 | -132.07% |
| Sep 30, 2022 | 65.88% |
| Jun 30, 2022 | 90.73% |
| Mar 31, 2022 | 39.92% |
| Dec 31, 2021 | 449.32% |
| Sep 30, 2021 | -422.12% |
| Jun 30, 2021 | -2,029.83% |